Projects

T20K – Lead Drug For MS

T20K is a unique compound that has been shown by the researchers in Vienna and Freiburg to inhibit pro-inflammatory cytokines such as IL2 and effectively reduce clinical symptoms in an animal model for multiple sclerosis after oral administration. At therapeutic, doses no signs of toxicity has been observed.

A Diverse Product Portfolio

Cyclotides can be modified, while keeping the core cyclotide drug structure, to introduce a variety of novel pharmaceutical properties for selected diseases. This offers a great opportunity for Cyxone to build a diverse product portfolio over time.

Cyxone is aiming to bring T20K through a clinical program for RMS with targeted market approval in year 2023

Literature

  • Thell, K., Hellinger, R., Schabbauer, G. and Gruber, C; Drug Discovery Today, vol. 19, No 5, 2014, 645-653
  • Gründemann,C, Thell, K, Lengen, K, Garcia-Käufer, M, Huang, Y-H, Huber, R., Craik, D.J., Schabbauer, G. and Gruber, C.W.; PLOS, June 2013